Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 11/20 | 0.46 |
| ▸ | PARP1 | P09874 | 3/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20836477 | 1.00 | GRM7 (0.46) | GRM7PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL21722287 | 0.77 | ADRA1A (0.40) | GRM7ADRA1AADRA1DMEN1KMT2A | |
| SCHEMBL31483699 | 0.73 | GRM7 (0.56) | GRM7RPS6KA3 | |
| SCHEMBL20836389 | 0.73 | GRM7 (0.56) | GRM7RPS6KA3 | |
| SCHEMBL21733758 | 0.73 | KMT2A (0.39) | PARP1MEN1HPGDKMT2A | |
| SCHEMBL31483678 | 0.72 | GRM7 (0.48) | GRM7 | |
| SCHEMBL20836353 | 0.72 | GRM7 (0.48) | GRM7 | |
| SCHEMBL30834503 | 0.72 | GRM7 (0.32) | GRM7ADRA1A | |
| SCHEMBL21722189 | 0.72 | GRM7 (0.32) | GRM7ADRA1A | |
| SCHEMBL24855076 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2025-08-14 | — | — | US | disclosed |
| CN-111148744-B | Novel heterocyclic compounds as MGLUR7 modulators | 布拉格玛治疗公司 | 2025-02-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | GRM7 1/4885PARP1 4766/4885CHEK1 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.